ImmunoLin
Commercial- Indications
- Chronic diarrhea, Gastrointestinal disorders
Company intelligence / Profile preview
Entera Health
Jerusalem, Israelenterabio.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Commercial
01
Overview
Completed Phase 2 clinical trial for EB613 for post-menopausal women with low bone mineral density and high-risk osteoporosis; Completed Phase 1 clinical trial to treat stress fractures; Developing EB612 for hypoparathyroidism
- Therapeutic areas
- Metabolic DisordersEndocrinologyGastroenterology
- Modalities
- Oral peptide and protein replacement therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Research collaboration agreement with OPKO Biologics, Inc.
Beyond the preview
Go deeper on Entera Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Entera Health.